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Abstract Most guidelines for the management of hospi-
talized patients with community-acquired pneumonia
(CAP) recommend commencing therapy with intravenous
antibiotics, primarily because of concern about absorption
of oral antibiotics in acutely ill patients. However,
patients who respond are rapidly switched to oral therapy,
which has been shown to reduce costs and to shorten the
length of stay. The aim of the present study was to
determine whether a full course of oral antibiotics is as
efficacious and as safe as intravenous-to-oral sequential
antibiotic therapy for the treatment of hospitalized, non-
ICU patients with CAP. In an open-labelled, controlled
study, 129 hospitalized patients with CAP were randomly
assigned in a 2:1 ratio to receive either a full course of
oral levofloxacin (500 mg q12 h) or an intravenous-to-
oral sequential therapy consisting of intravenous ceftri-
axone (2 g q24 h) with or without clarithromycin (500 mg
q12 h) followed by an oral antibiotic (a beta-lactam agent
in the majority of patients). The primary study endpoint
was the resolution of CAP; secondary endpoints included
length of stay and overall mortality. CAP resolved in 72
of 79 (91.1%) patients in the levofloxacin group and in 34
of 37 (91.9%) patients in the intravenous-to-oral sequen-
tial therapy group (difference, 0.8%, 95%CI, 11.6–
10.0). Median length of stay was 8 days (range, 2–74
days) in the levofloxacin group and 10 days (range, 3–29
days) in the intravenous-to-oral sequential therapy group
(P=0.28). Day 30 mortality rates were 1.3% (1 of 79) and
8.1% (3 of 37), respectively (difference, 6.8%, 95%CI,
16.0–2.3). Full-course oral levofloxacin is as efficacious
and as safe as standard intravenous-to-oral sequential
antibiotic therapy for the treatment of hospitalized
patients with CAP.
Introduction
With the exception of the guidelines of the British
Thoracic Society, which encourage oral therapy for
nonsevere cases [1], most guidelines for the management
of hospitalized patients with community-acquired pneu-
monia (CAP) generally recommend commencing therapy
with intravenous antibiotics [2, 3, 4]. However, the choice
of parenteral over oral therapy is guided by prudence
rather than by clinical evidence of superiority, primarily
because of concern about absorption of oral antibiotics in
critically ill patients. Moreover, patients who improve
clinically are rapidly switched to oral therapy, usually
within 3 days, since intravenous-to-oral sequential or
step-down therapy has been shown to be safe, to reduce
treatment costs and to shorten the length of stay [5, 6, 7, 8,
9, 10, 11, 12, 13]. We therefore evaluated the efficacy and
safety of a full course of oral antibiotics for the treatment
of patients hospitalized with CAP.
Fluoroquinolones with enhanced activity against pneu-
mococci (such as levofloxacin, gatifloxacin and moxi-
floxacin) have become important agents in the
management of patients with CAP due to their excellent
bioavailability, their broad-spectrum antimicrobial activ-
ity against gram-positive, gram-negative and atypical
intracellular bacteria, and their favourable safety profile,
[2, 3, 4]. Amongst the fluoroquinolones, levofloxacin has
been shown to be highly efficacious when given orally to
V. Erard · P.-Y. Bochud · A. Cometta · T. Calandra ())
Division of Infectious Diseases,
Centre Hospitalier Universitaire Vaudois,
1011 Lausanne, Switzerland
e-mail: Thierry.Calandra@chuv.hospvd.ch
Tel.: +41-21-314-1037
Fax: +41-21-314-1036
O. Lamy
Department of Internal Medicine (Service A),
Centre Hospitalier Universitaire Vaudois,
1011 Lausanne, Switzerland
J. Bille
Institute of Microbiology,
Centre Hospitalier Universitaire Vaudois,
1011 Lausanne, Switzerland
A. Cometta
Service of Medicine,
Centre Hospitalier Yverdon-Chamblon,
1400 Yverdon-les-Bains, Switzerland
outpatients or as intravenous-to-oral sequential therapy to
inpatients with CAP [12, 14, 15]. The efficacy and safety
of a full course of oral levofloxacin was thus compared
with that of a standard intravenous-to-oral sequential
therapy, which consisted of intravenous ceftriaxone (2 g
q24 h) with or without clarithromycin (500 mg q12 h)
followed by an oral antibiotic (a beta-lactam agent in the
majority of patients) for the treatment of hospitalized,
non-ICU adult patients with CAP. The study was
designed as an open-labelled, randomized, controlled
pilot observational study to assess the feasibility and
safety of oral antibiotic therapy in these patients.
Materials and Methods
Patients
All consecutive adult patients (age 18 years) admitted for the
treatment of CAP were eligible for enrolment if they met the
following criteria: presence of a newly acquired pulmonary
infiltrate on a chest radiograph compatible with pneumonia and
at least one of the following symptoms or signs that developed
within 48 h of admission: fever (>38C), chills, dyspnoea, cough,
sputum production, pleuritic chest pain, altered breath sounds, dull
percussion sounds, bronchial rales or pleural rub. Exclusion criteria
included admission to an ICU; high likelihood of being discharged
from hospital within 24 h of admission; previous hospitalization or
stay in a nursing home within 10 days and 4 weeks of admission,
respectively; inability to take oral medication; and presence of any
of the following conditions or diseases: pregnancy, cystic fibrosis,
epilepsy, neutropenia defined as a neutrophil count of less than
500 cells/mm3, organ transplantation, treatment with cytotoxic or
immunosuppressive agents other than corticosteroids for the
treatment of chronic obstructive pulmonary disease, infection with
the human immunodeficiency virus, treatment with a fluoro-
quinolone within 1 week of admission and history of allergy to
beta-lactam or fluoroquinolone antibiotics.
Study Design and Setting
The study was designed as a prospective, randomized, open-
labelled, controlled pilot observational study conducted in two
Swiss medical centres: a 900-bed teaching hospital that serves as
both as city hospital and a tertiary reference centre providing
services to an area populated with more than 500,000 inhabitants
(Centre Hospitalier Universitaire Vaudois, Lausanne) and a 160-
bed community hospital (Centre Hospitalier Yverdon-Chamblon,
Yverdon-les-Bains). The study was approved by the ethics
committees of both institutions, and written informed consent
was obtained from each patient or legal guardian.
Patients were randomized in a 2:1 ratio to receive a full course
of oral levofloxacin (500 mg q12 h) or an intravenous-to-oral
sequential therapy regimen consisting of intravenous ceftriaxone
(2 g q24 h) with or without concomitant intravenous or oral
clarithromycin (500 mg q12 h) followed by an oral antibiotic
therapy chosen by the physician-in-charge according to CAP
treatment guidelines in use at the participating institutions [16]. The
choice of a 2:1 ratio was guided by the desire to expose more
patients to oral than conventional intravenous-to-oral sequential
therapy in this pilot feasibility study. The addition of clar-
ithromycin was recommended in patients who presented with
hyponatremia, elevated liver enzymes, unexplained diarrhoea,
elevation of creatine phosphokinase, altered mental status, oligoa-
nuria, elevated respiratory rate (>30/min) and/or hypotension
(systolic or diastolic blood pressure of less than 90 or 60 mmHg,
respectively).
Intravenous-to-oral switch was recommended after 2–3 days of
therapy in patients with clinical evidence of improvement (such as
temperature of <38C and respiratory rate <24/min) who were able
to tolerate oral medication and had intact gastrointestinal motility.
Recommended duration of antibiotic therapy was 7–10 days.
Patients with suspected or proven Mycoplasma pneumoniae,
Chlamydia pneumoniae or Legionella pneumophila pneumonia or
necrotizing pneumonia such as that due to Staphylococcus aureus,
enteric gram-negative bacteria or Pseudomonas aeruginosa were
treated for 2–3 weeks with appropriate antibiotics on the basis of
the results of in vitro susceptibility tests. In patients with renal
failure, daily doses of levofloxacin were adapted on the basis of
creatinine clearance as calculated according to Cockcroft and Gault
[17].
Clinical and Laboratory Evaluation
The study protocol required that, whenever possible, the following
be performed prior to the initiation of antibiotic therapy: a complete
medical history; physical examination; chest radiograph; oxygen
saturation test; haematological investigations (determination of
haemoglobin, haematocrit, leucocyte and platelet counts); bio-
chemistry tests (determination of electrolytes, urea, creatinine,
bilirubin, serum transaminase, alkaline phosphatase and C-reactive
protein); two sets of blood cultures; and Gram stain and cultures of
expectorated sputum, pleural fluid or any other infected sites.
Except in cases of suspected Legionella pneumonia, Gram stain of
sputum was considered to be evaluable and was accepted for
culture if it contained fewer than 25 epithelial cells per low-power
field [18]. Identification of the microorganisms and antibiotic
susceptibility testing were performed according to standard proce-
dures [19, 20]. Urinary antigen detection tests for Streptococcus
pneumoniae (Binax NOW ICT Streptococcus pneumoniae) and
Legionella pneumophila serogroup 1 (Binax NOW ICT Legionella)
were performed in every patient (Streptococcus pneumoniae) or
whenever Legionnaire’s disease was suspected. Serological anal-
yses for respiratory pathogens were not performed on a routine
basis. Follow-up studies were performed as clinically indicated and
until resolution of laboratory test abnormalities or discharge of the
patient from hospital. Symptoms and clinical signs were evaluated
by a research nurse and by the infectious diseases fellow in charge
of the study, daily during the first week and thereafter every other
day. Severity of CAP was assessed by the Prognostic Score Index
proposed by Fine et al. [21].
Definitions
The etiological diagnosis of CAP was considered definitive when
Streptococcus pneumoniae or a likely respiratory pathogen (such as
Haemophilus influenzae or Moraxella catarrhalis) was isolated
from blood cultures, an uncontaminated specimen (i.e. pleural fluid
or transthoracic aspirate) or expectorated sputum; when the urinary
Legionella pneumophila antigen test was positive; or when there
was a greater than or equal to fourfold increase in antibody titres to
Legionella pneumophila, Mycoplasma pneumoniae or Chlamydia
pneumoniae. The etiological diagnosis of CAP was considered
probable when a urinary Streptococcus pneumoniae capsular
antigen test was positive or when the expectorated sputum was
positive for uncommon respiratory pathogens (such as enteric
gram-negative bacteria or Staphylococcus aureus) that were
predominant on Gram stain.
Evaluation of Response and Adverse Events
The primary study endpoint was the resolution of CAP, evaluated
on day 30. Secondary endpoints included overall and infection-
related day 30-mortality (checked by a phone call for patients who
had been discharged) and length of hospital stay. Clinical response
was evaluated as a success if clinical signs and symptoms of
83
infection and laboratory test abnormalities resolved and the
infecting microorganism was eradicated (for patients with a
microbiologically documented infection). Clinical response was
evaluated as a failure in the event of the following: (i) the patient
died of pneumonia, (ii) pneumonia did not improve or worsened
under antibiotic therapy, (iii) pneumonia relapsed within 7 days
after discontinuation of antibiotics or (iv) an adverse event occurred
that required discontinuation of therapy. All patients who received
at least one dose of the study drug were evaluated for adverse
events, which were classified as possibly, probably or definitely
related to antibiotic therapy. Relapse was assessed by phone call on
day 30.
Statistical Analysis
Categorical variables were compared using the chi-square test. In
two-by-two situations, Yate’s correction for continuity was used,
whereas Fisher’s exact test was used when any cell size was less
than five. For continuous variables, the nonparametric Mann-
Whitney test was used to compare the distribution between the two
treatment groups. All reported significance levels are two-sided.
The SPSS program was used for statistical computations (SPSS for
Windows, 1999).
Results
From April 2000 to April 2001, 201 patients admitted
with CAP were screened, 144 were eligible for the study,
15 refused to participate and 129 were randomized.
Thirteen patients were withdrawn from the study for the
following reasons: primary diagnosis other than CAP (10
patients), lost to follow-up (2 patients) or discharge from
hospital within 24 h of admission (1 patient). Thus, 116
patients (oral levofloxacin, 79; intravenous-to-oral se-
quential therapy, 37) were evaluable for response to
antibiotic in a per-protocol analysis. Characteristics of the
patients (Table 1) were comparable in the two treatment
groups except for the higher median baseline serum
creatinine level in the levofloxacin group (102 vs. 94
mmol/l, P=0.02). In both treatment groups, more than
60% of the patients had a Prognostic Score Index of IV or
V, and more than 70% of the patients had comorbidities,
mostly cardiopulmonary diseases. Sixteen (14%) patients
had received antibiotics (median duration of therapy, 1.5
days) prior to admission.
Table 1 Characteristics of the
patients included in the study
Characteristic Oral levofloxacin group lntravenous-to-oral sequential
therapy group
Total no. of patients 79 37
No. of males/females 46/33 25/12
Median age in years (range) 77 (24–92) 77 (26–95)
Prognostic Score Index, no. (%)
I 0 (0%) 1 (3%)
II 14 (18%) 8 (22%)
III 14 (18%) 5 (14%)
IV 47 (59%) 20 (54%)
V 4 (5%) 3 (8%)
Previous antibiotics, no. (%) 12 (15%) 4 (5%)
Comorbiditiesa, no. (%) 57 (72%) 27 (73%)
Heart failure 36 (46%) 12 (32%)
COPD 24 (30%) 11 (30%)
Asthma 5 (6%) 2 (5%)
Diabetes 4 (5%) 3 (8%)
Renal failure 12 (15%) 2 (5%)
Cancer 5 (6%) 1 (3%)
Cerebrovascular diseases 3 (3%) 5 (13%)
Liver disease 2 (3%) 0 (0%)
Neuromuscular disease 1 (1%) 1 (3%)
Median clinical parameters (range)
Temperature, C 38 (36–40) 38 (35–40)
Heart rate, min-1 97 (54–160) 103 (67–140)
Systolic pressure, mmHg 130 (98–190) 134 (113–192)
Diastolic pressure, mmHg 80 (60–135) 80 (58–110)
Respiratory rate, min-1 22 (9–36) 24 (12–52)
Median laboratory parameters (range)
Leucocyte count, 103/mm3 12.4 (5.1–35.5) 13.8 (4.8–30)
C-reactive protein, mg/l 143 (1–450) 171 (10–513)
Creatinine, mmol/lb 102 (61–320) 94 (65–167)
Sodium, mmol/l 136 (125–143) 135 (116–140)
Abnormal chest radiograph, no. (%) 79 (100%) 37 (100%)
Bilateral infiltrate 9 (11%) 3 (8%)
More than 1 lobe involved 13 (16%) 3 (8%)
COPD, chronic obstructive pulmonary disease
a Some patients had more than one comorbidity
b P=0.04
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Blood cultures were performed in 76 (66%) patients
and were positive in 4. Bacteraemia was due to Strepto-
coccus pneumoniae (2 episodes) and to Staphylococcus
aureus and group G streptococci (1 episode) in the
levofloxacin group and to Streptococcus pneumoniae (1
episode) in the intravenous-to-oral sequential therapy
group. Cultures of expectorated sputum were performed
in 46 (40%) patients, and Streptococcus pneumoniae and
Legionella urinary antigens were measured in 79 (68%)
patients and 26 (22%) patients, respectively. Pneumonia
was microbiologically documented in 29 (25%) patients
(Table 2). The aetiology of pneumonia was considered
definitive in 15 patients and probable in 14. Streptococcus
pneumoniae was the most common pathogen (66%),
followed by Haemophilus influenzae (14%), Staphylo-
coccus aureus (7%), Moraxella catarrhalis (7%) and
Escherichia coli (7%). Five patients had mixed infections
due to Streptococcus pneumoniae and Haemophilus
influenzae in three, Streptococcus pneumoniae and Mo-
raxella catarrhalis in one and Staphylococcus aureus and
group G streptococci in one. All isolates of Streptococcus
pneumoniae were susceptible to levofloxacin and to
ceftriaxone, 71% were susceptible to penicillin G and
57% were susceptible to clarithromycin.
The median duration of antibiotic therapy was 11 days
(range, 5–22 days) in the levofloxacin group and 13 days
(range, 9–28 days) in the intravenous-to-oral sequential
therapy group (P=0.01). In the levofloxacin group, two
patients received the first dose of antibiotic intravenously.
In the intravenous-to-oral sequential therapy group, 20
(54%) patients were treated with ceftriaxone plus oral
clarithromycin and 17 (46%) patients with ceftriaxone
monotherapy. The median duration of intravenous ceftri-
axone was 4 days (range, 2–11 days). Five patients
received a full course of intravenous therapy, given in
combination with clarithromycin in two, whereas 32
patients were switched to oral therapy consisting of
amoxicillin/clavulanate (17 patients), cefuroxime (7 pa-
tients), clarithromycin (4 patients) or levofloxacin (4
patients). Clinical response rates were similar in both
treatment groups (levofloxacin, 91.1%; intravenous-to-
oral sequential therapy, 91.9%; difference, 0.8%;
95%CI, 11.6–10.0) (Table 3). Treatment failures were
due to nonresponse, reinfection or adverse events, each
occurring in three patients. Antibiotics had to be changed
after 3, 5 and 7 days, respectively, due to lack of clinical
improvement in 3 patients (levofloxacin group, 2; intra-
venous-to-oral sequential therapy group, 1) with CAP of
undetermined aetiology. All patients improved after
Table 2 Etiology of pneumonia
in the study patients
Etiological characteristic Oral levofloxacin
group
lntravenous-to-oral sequential
therapy group
No. of patients 79 37
No. (%) with microbiologically
documented pneumonia
18 (23%) 11 (30%)
No. of microorganisms isolateda 22 12
Gram-positive bacteria
Streptococcus pneumoniae 11 8
Staphyolococcus aureus 2 0
Group G streptococci 1 0
Gram-negative bacteria
Haemophilus influenzae 3 1
Escherichia coli 1 1
Moraxella catarrhalis 2 0
Klebsiella pneumoniae 0 1
Legionella pneumophila 1 0
Pasteurella multocida 1 0
Other 0 1
a More than 1 microorganism was isolated in 5 patients (Streptococcus pneumoniae and Haemophilus
influenzae in 3, Streptococcus pneumoniae and Moraxella catarrhalis in 1 and Staphylococcus aureus
and group G streptococci in 1)
Table 3 Outcome of the pa-
tients included in the study
Outcome Oral levofloxacin
group
lntravenous-to-oral sequential
therapy group
No. of patients 79 37
Cure, no. (%) 72 (91.1%) 34 (91.9%)
Failure, no. (%) 7 (8.9%) 3 (8.1%)
Nonresponse, no. (%) 2 (2.5%) 1 (2.7%)
Relapse/reinfection, no. (%) 2 (2.5%) 1 (2.7%)
Death due to infection, no. (%) 0 (0%) 1 (2.7%)
Adverse event(s), no. (%) 3 (3.8%) 0 (0%)
Median length of stay in days (range) 8 (2–74) 10 (3–29)
Overall mortality at day 30, no. (%) 1 (1.3%) 3 (8.1%)
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modification of antibiotic therapy. One patient in the
levafloxacin group was readmitted because of relapsing
CAP due to a penicillin- and macrolide-susceptible strain
of Streptococcus pneumoniae; relapse occurred 7 days
after discontinuation of levofloxacin for the first of
episode of CAP, for which no microorganism had been
isolated. Unfortunately, the susceptibility of the Strepto-
coccus pneumoniae isolate to levofloxacin was not tested.
Pneumococcal pneumonia was cured with intravenous
ceftriaxone followed by oral cefuroxime. The other two
patients (levofloxacin group, 1; intravenous-to-oral se-
quential therapy group, 1) presented with acute bronchitis
7 and 10 days after discontinuation of antibiotic therapy.
These upper respiratory tract infections were not present
when the patients were enrolled into the study.
The median length of stay was 8 days (range, 2–74
days) in the levofloxacin group and 10 days (range, 3–29
days) in the intravenous-to-oral sequential therapy group
(P=0.28). Four patients died (overall mortality, 3.4%)
(levofloxacin group, 1 [1.3%]; intravenous-to-oral se-
quential therapy, 3 [8.1%]; difference, 6.8%;
95%CI,16.0–2.3), all of whom had a Prognostic Score
Index of IV and were 79–87 years of age. Pneumonia was
considered the cause of death in only one patient
(intravenous-to-oral sequential therapy group), who had
severe chronic obstructive pulmonary disease and died on
day 12 despite treatment with broad-spectrum intravenous
antibiotics. Blood and expectorated sputum cultures
remained negative, and no autopsy was performed. In
the other three patients, death was attributed to cardiac (2
patients) or digestive (1 patient) events. Antibiotic-
associated adverse events occurred in five (6%) patients
in the levofloxacin group and two (5%) patients in the
intravenous-to-oral sequential therapy group. The adverse
events reported in the levofloxacin group were nausea (2
patients), diarrhoea (2 patients) and seizure (1 patient).
Treatment was discontinued in three patients, but the
relationship between the adverse event and the study drug
was not established definitively. In the intravenous-to-oral
sequential therapy group, one patient developed nausea
that was possibly related to the study drug(s), and one had
Clostridium difficile colitis, considered definitely related
to antibiotic therapy.
Discussion
Until recently, administration of parenteral antibiotics
was considered the standard of care for the treatment of
infections in acutely ill hospitalized patients, including
patients with CAP. However, the advent of potent, broad-
spectrum, bactericidal antibiotics with excellent bioavail-
ability, such as beta-lactam agents and fluoroquinolones,
has offered clinicians the option to safely treat moderately
ill patients with oral antibiotics. Recent studies have
indeed shown that fluoroquinolones with enhanced activ-
ity against pneumococci, given either orally to outpatients
or as intravenous-to-oral sequential or step-down therapy
to inpatients, are highly efficacious and safe for the
treatment of patients with CAP [14, 22, 23, 24, 25, 26, 27,
28, 29].
The results of the present study show that a full oral
course of levofloxacin is as efficacious (response rate,
91% in levafloxacin group vs. 92% in intravenous-to-to
oral therapy group) and as safe (rate of adverse events,
6% vs. 5%; mortality, 1% vs. 8%) as standard intrave-
nous-to-oral step-down therapy for the treatment of
hospitalized patients with CAP. As a safeguard against
the risk of underdosing due to a less-than-optimal
absorption of oral antibiotic in these severely ill patients,
levofloxacin (500 mg) was given twice daily instead of
once daily as usually prescribed in patients with CAP.
The high proportion of patients with a Prognostic Score
Index of IV or V (>60%), the high rate of patients with
comorbidities (>70%) and the elevated median age (77
years) indicate that most of the patients enrolled were
critically ill [2, 3, 4, 21]. The high response rate (91%)
and the low mortality rate (1.3%) in the levofloxacin
group are comparable with those observed in numerous
intravenous-to-oral sequential studies and demonstrate the
efficacy and safety of a fully oral antibiotic treatment for
inpatients with CAP. Given their favourable antimicrobi-
al, clinical and safety profiles, fluoroquinolones with
enhanced activity against Streptococcus pneumoniae are
now widely used for the treatment of CAP, especially in
areas with high rates of resistance to penicillin and
macrolides. However, as a word of caution against the
indiscriminate use of this class of antibiotics, especially in
the context of low resistance to other commonly used
antibiotics or for the treatment of outpatients with
uncomplicated CAP, physicians should be aware that
resistance is emerging [30], as might have occurred in one
of our patients, and that treatment failures have been
reported [31].
Treatment with oral antibiotics helps minimize the use
of intravenous catheters, thereby reducing nursing time
and improving the patient’s comfort and mobility and thus
preventing complications of intravenous therapy such as
phlebitis, catheter-related infections, bedsores and throm-
boembolic events. Moreover, previous studies have
demonstrated that an early switch from intravenous to
oral antibiotics in patients with CAP reduces treatment
costs and shortens the length of hospital stay [5, 6, 7, 8, 9,
10, 11, 12, 13]. The median length of stay was numer-
ically lower (8 vs. 10 days) in the oral therapy group than
in the intravenous therapy group, but this difference was
not statistically significant. This was not unexpected.
Indeed, in a mostly elderly patient population with
frequent comorbidities, the management of the underlying
diseases rather than the treatment of CAP and the time
needed to find an appropriate social environment com-
patible with a safe return to home usually are the main
determinants of the length of stay [4]. Administration of a
full oral course of antibiotics may help to further shorten
the patient’s hospital stay without comorbidities.
Few studies have examined the feasibility of an
exclusively oral therapy for inpatients with CAP. The
first studies were conducted with penicillin V, cefpo-
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doxime, ofloxacin or azithromycin [32, 33, 34, 35], which
are either no longer appropriate or could only be used in a
minority of hospitalized patients with CAP [2, 3, 4]. More
recently, oral cefuroxime therapy and amoxicillin/clavu-
lanate given with or without a macrolide were observed to
be as efficacious as intravenous-to-oral step-down therapy
in 85 hospitalized patients with nonsevere CAP [36]. Only
two studies have compared the efficacy of fluoro-
quinolone monotherapy with that of standard oral or
intravenous antibiotics [15, 37]. Once-daily oral spar-
floxacin was shown to be as efficacious as oral amoxi-
cillin in a prospective, randomized trial of mostly young
inpatients with CAP and no comorbidities [37]. In the
other study, conducted in a sicker patient population,
intravenous-to-oral sequential levofloxaxin was found to
be as effective as intravenous ceftriaxone followed by
various oral antibiotics or cefpodoxime for inpatients with
CAP [15]. Therefore, the present observational and
feasibility study strongly suggests that a full course of
oral fluoroquinolone therapy is as efficacious as standard
intravenous-to-oral step-down therapy for the treatment of
hospitalized non-ICU adult patients with CAP.
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